The Economic Domain within Health Technology Assessments (HTA): An international comparison of methodology and the impact on health policy decisions

Reinhard Busse, Prof. Dr. med. MPH
Department of Health Care Management
Berlin University of Technology
(WHO Collaborating Centre for Health Systems Research and Management)
&
European Observatory on Health Systems and Policies
Introduction

• Economic aspects, i.e. costs (per patient/person as well as overall [budget impact]) and cost-effectiveness, are one of nine domains in EUnetHTA’s CORE model.

• However, there is currently no accepted guideline for economic evaluations within EUnetHTA, apart from some general recommendations related to the CORE model.

• As HTA is becoming more European, and with the Commission having proposed a proposal to standardize HTA within the EU*, both to understand methodological differences across countries and to define common standards seems ever more urgent.
*New EC proposal to assess clinical aspects uniformly ...*

The proposal establishes a requirement for mandatory use of the joint clinical assessment report and no repetition of the assessment in Member States' overall HTA processes. This means that Member States will continue to carry out non-clinical assessments i.e. on the non-clinical HTA domains (e.g. economic, organisational, ethical) and will draw conclusions on the overall added value of the assessed health technology based on the joint clinical assessment report and their own non-clinical assessment.
Methods

• The EUnetHTA Joint Action in its second phase (2012-2016) tackled these two issues, by
  (1) **undertaking a review of methods** for economic evaluation within HTA across 33 countries (incl. all EU member states) and
  (2) **evaluating the feasibility of defining a general framework** for EUnetHTA on how to conduct economic evaluations as well as
  to increase the transferability of economic evaluations among EUnetHTA partners.

• The resulting draft guideline is thus based on a review of methodological guidelines developed by the partners of EUnetHTA.
Results I

- 25 of the 33 countries reported having some kind of methodological guideline for health economic evaluations (in total 51 guidelines).

- Guidelines for health economic evaluations regarding pharmaceuticals were most common (n= 28), followed by general guidelines that apply to any type of health interventions (n= 19), but some countries also have guidelines for other types of health interventions (e.g. diagnostics and medical devices).
Results II

• On certain methodological issues, the various agencies have a **common view** (e.g. the time horizon of the analysis, *presentation of results*, and use of decision models), i.e. finding a “European way” should be straightforward.

• On other issues, there was **less agreement** (e.g. choice of *outcome measure*, *perspective* of the analysis, *presentation of data on resource use*, and how to analyse the uncertainty related to the results), but EUnetHTA is hopeful to find a common ground.

• For yet another set of methodological issues, the EUnetHTA partners have **clearly different views**, e.g. regarding the acceptability of some outcome measures, *costs to be included*, the *rates for discounting costs and effects*, as well as on the methods for deriving health-related quality of life (HRQoL) weights for calculation of quality-adjusted life years (QALYs).
## Economic guidelines on various aspects I

<table>
<thead>
<tr>
<th>Outcome measure (partly dependent on type of evaluation)</th>
<th>QALYs</th>
<th>Life Years Gained</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AT, BE, HR, CZ, DK, GB-E, FI, FR, HU, IE, IT, NL, NO, PL, RU, GB-S, SK*, SI, ES, SE</td>
<td>AT, BE, CZ, DK, FR, NL, PL, PT, RU, SK*, SE**</td>
<td>HR, CZ, DK, GB-E, EE, DE, LV, PL, PT, RU, SK***, CH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Presentation</th>
<th>ICER</th>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AT, BE, HR, CZ, GB-E, EE, FI, FR, HU, IE, IT, LV, NL, PT, RU, GB-S, SI, ES, SE</td>
<td>DK, DE, NO, PT, RU, SK, CH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Perspective</th>
<th>Payer</th>
<th>Society</th>
<th>Variable</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>BE, CZ, EE, GB-E, DE, IE, IT, HR, PL, GB-S, SK, SI, ES</td>
<td>DK, FI, FR#, NL, NO, PL, GB-S, ES, SE</td>
<td>AT, PL, GB-S, ES</td>
</tr>
</tbody>
</table>

* Chronic conditions; ** if survival relevant; *** other conditions; # All payers + patients
### Economic guidelines on various aspects II

<table>
<thead>
<tr>
<th>Costs to be included (partly dependent on perspective)</th>
<th>All (direct &amp; indirect)</th>
<th>AT*, DK, HU, NL, PL**, PT, RU, ES, SE, CH***</th>
</tr>
</thead>
<tbody>
<tr>
<td>All direct</td>
<td>AT, FR, IT, NO****, CH</td>
<td></td>
</tr>
<tr>
<td>All direct but OOP excl.</td>
<td>GB-E</td>
<td></td>
</tr>
<tr>
<td>Medical direct plus OOP</td>
<td>DE</td>
<td></td>
</tr>
<tr>
<td>Medical direct</td>
<td>BE, EE, FI, LV, SK, SI</td>
<td></td>
</tr>
<tr>
<td>Payer’s direct only</td>
<td>HR, CZ, IE, GB-S</td>
<td></td>
</tr>
</tbody>
</table>

* If societal perspective; ** separated into direct medical/ direct non-medical/ indirect; *** if savings from indirect costs are significant; **** indirect may be presented separately
Economic guidelines III: discounting costs vs. effects, rates

Discounting of costs and health outcomes

- Belgium and the Netherlands:
  Costs: 3-4%
  Effects: 1.5%

- Poland:
  Costs: 5%
  Effects: 3.5%

- Russia:
  Costs: 5%
  Effects: 0%

Spain (Spanish recommendations and CatSalut), Austria, Croatia, Finland, Germany, Italy, Sweden, England, Scotland, Hungary, France, Norway, Estonia and Latvia, Ireland, Portugal, Slovakia, Spain (OSTEBA) with various discount rates as shown in the chart.

Fig. 1 Discounting of costs and effects recommended in the partner countries. CatSalut Catalan Health Service, OSTEBA Basque Office for Health Technology Assessment.

Heintz et al. 2015
Conclusion

• EUnetHTA’s (draft) guideline constitute an important step towards a common European view on conducting health economic evaluations within HTA.

• Whether progress will be fast enough to keep pace with the Commission’s intentions remains to be seen (but the Commission will most likely be slowed down by the member states).

• The next politically sensitive issue after finding agreement on a common methodology will be a discussion about harmonizing decision criteria.